Regeneration, Tutogen merge in $263M stock deal

November 2007
Medical Technology & Devices Week;11/19/2007, Vol. 5 Issue 46, p3
The article reports on the plan of Regeneration Technologies and Tutogen Medical to merge in a tax free, stock-for-stock deal worth about $263 million. The deal is expected to close in the first quarter of 2008. Tutogen creates sterile biological implant products made from human and animal tissue, while Regeneration processes human and animal tissue into shaped implants for use in orthopedic and other surgeries with a commitment to science, safety and innovation. Terms of the deal is presented.


Related Articles

  • Deals roundup.  // Medical Device Daily;1/15/2008, Vol. 12 Issue 10, p3 

    The article reports that meetings of stockholders of Regeneration Technologies and Tutogen Medical have been scheduled. The aim of the meetings is to vote for the merger of the two companies. The schedule of the meeting is after January 7, 2008 which is the expiry date of the waiting period...

  • CORPORATE.  // MondayMorning;11/19/2007, Vol. 15 Issue 46, p2 

    This section offers business news briefs in the U.S. pharmaceutical industry. Regeneration Technologies Inc., a specialist in tissue implants, plans to acquire Tutogen Medical Inc. of West Paterson, New Jersey. New York-based Pfizer Inc. plans to acquire its former partner Coley Pharmaceutical...

  • Regeneration, Tutogen to merge in $263M stock-for-stock deal. Pedersen, Amanda // Medical Device Daily;11/14/2007, Vol. 11 Issue 219, p1 

    The article reveals the plan of Regeneration Technologies and Tutogen Medical to merge in a stock-for-stock deal. A total of 1.22 shares of newly issued Regeneration common stock will be received by Tutogen shareholders in exchange for each share of Tutogen common stock they own. According to...

  • Thomson Financial Worldwide Mergers & Acquisitions.  // Mergers & Acquisitions Report;11/19/2007, Vol. 20 Issue 44, p8 

    This section offers news briefs on worldwide mergers and acquisitions. Regeneration Technologies Inc. agreed to merge with Tutogen Medical Inc. Catterton Partners agreed to acquire all the outstanding common stock of Restoration Hardware Inc. Esco Technologies Inc. agreed to acquire Doble...

  • Deals roundup.  // Medical Device Daily;1/18/2008, Vol. 12 Issue 13, p4 

    This article focuses on the proposed merger between Regeneration Technologies and Tutogen Medical. RTI Biologics is the proposed new name of the merged companies. There is a plan to position the new company as a leader in biologics. A stockholder meeting will be held in February 2008 to vote on...

  • RESONANT ACOUSTIC METHOD DELIVERS DEFECT-FREE PARTS. Bono, Richard; Soreven, Scott // Advanced Materials & Processes;Jul2008, Vol. 166 Issue 7, p25 

    Several news briefs regarding the biomaterial industry are presented. Invibio Biomaterial Solutions and Smith & Nephew have agreed upon a research collaboration to develop structural bioresorbable polymers. The Sigma Knee group expanded their offerings of knee replacement implants to fit a wider...

  • Wright and Regeneration to develop xenograft implants.  // Advanced Materials & Processes;Apr2007, Vol. 165 Issue 4, p46 

    The article reports on Wright Medical Group Inc.'s agreement with Regeneration Technologies Inc. (RTI) to develop advanced xenograft implants for foot and ankle surgeries. The design will be done by Wright Medical and manufacturing by RTI. The product is noted for its uses as a biomaterial in...

  • Deals roundup.  // Medical Device Daily;12/26/2007, Vol. 11 Issue 233, p3 

    The article reports that LeMaitre Vascular, a provider of peripheral vascular devices and implants, has acquired all the stock of Biomateriali S.r.I. for €1.8 million in cash. According to George LeMaitre, CEO and chairman of LeMaitre, the high quality vascular grafts of Biomateriali fit...

  • Zimmer Holdings. Wang, Debbie S. // Morningstar GrowthInvestor;Jul2006, Vol. 2 Issue 2, p6 

    Analyzes the stock performance of Zimmer Holdings, a company involved in the reconstructive-implant industry. Impact of Zimmer's acquisition of Centerpulse on its status in the orthopedic device industry; Concern about near-term pricing pressure; Outlook on the growth of the stock.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics